Logo image of NLSP

NLS PHARMACEUTICS LTD (NLSP) Stock Fundamental Analysis

NASDAQ:NLSP - Nasdaq - CH1384053976 - Common Stock - Currency: USD

2.34  +0.07 (+3.08%)

Fundamental Rating

2

Taking everything into account, NLSP scores 2 out of 10 in our fundamental rating. NLSP was compared to 195 industry peers in the Pharmaceuticals industry. While NLSP seems to be doing ok healthwise, there are quite some concerns on its profitability. NLSP has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NLSP had negative earnings in the past year.
In the past year NLSP has reported a negative cash flow from operations.
NLSP had negative earnings in each of the past 5 years.
NLSP had a negative operating cash flow in each of the past 5 years.
NLSP Yearly Net Income VS EBIT VS OCF VS FCFNLSP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

Looking at the Return On Assets, with a value of -181.68%, NLSP is doing worse than 89.23% of the companies in the same industry.
NLSP's Return On Equity of -288.47% is on the low side compared to the rest of the industry. NLSP is outperformed by 74.87% of its industry peers.
Industry RankSector Rank
ROA -181.68%
ROE -288.47%
ROIC N/A
ROA(3y)-339.54%
ROA(5y)-292.49%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NLSP Yearly ROA, ROE, ROICNLSP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

NLSP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NLSP Yearly Profit, Operating, Gross MarginsNLSP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for NLSP has been increased compared to 1 year ago.
NLSP has less shares outstanding than it did 5 years ago.
NLSP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NLSP Yearly Shares OutstandingNLSP Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
NLSP Yearly Total Debt VS Total AssetsNLSP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

2.2 Solvency

Based on the Altman-Z score of -45.35, we must say that NLSP is in the distress zone and has some risk of bankruptcy.
NLSP's Altman-Z score of -45.35 is on the low side compared to the rest of the industry. NLSP is outperformed by 90.26% of its industry peers.
There is no outstanding debt for NLSP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -45.35
ROIC/WACCN/A
WACCN/A
NLSP Yearly LT Debt VS Equity VS FCFNLSP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

2.3 Liquidity

NLSP has a Current Ratio of 2.69. This indicates that NLSP is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.69, NLSP is in line with its industry, outperforming 46.67% of the companies in the same industry.
A Quick Ratio of 2.69 indicates that NLSP has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.69, NLSP is in line with its industry, outperforming 51.28% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.69
Quick Ratio 2.69
NLSP Yearly Current Assets VS Current LiabilitesNLSP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 77.00% over the past year.
EPS 1Y (TTM)77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.24%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y71.88%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NLSP Yearly EPS VS EstimatesNLSP Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 -5 -10 -15 -20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NLSP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NLSP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NLSP Price Earnings VS Forward Price EarningsNLSP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NLSP Per share dataNLSP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NLSP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NLS PHARMACEUTICS LTD

NASDAQ:NLSP (6/17/2025, 11:21:01 AM)

2.34

+0.07 (+3.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-16 2025-05-16/amc
Earnings (Next)N/A N/A
Inst Owners6.44%
Inst Owner Change0%
Ins Owners27.97%
Ins Owner ChangeN/A
Market Cap8.42M
Analysts43.33
Price TargetN/A
Short Float %5.36%
Short Ratio0.58
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.99
P/tB 5.99
EV/EBITDA N/A
EPS(TTM)-2.93
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)-1.19
OCFYN/A
SpS0
BVpS0.39
TBVpS0.39
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -181.68%
ROE -288.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-339.54%
ROA(5y)-292.49%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 118.18%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.69
Quick Ratio 2.69
Altman-Z -45.35
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)39.39%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.24%
EPS Next Y71.88%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y69.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y55.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.93%
OCF growth 3YN/A
OCF growth 5YN/A